Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Indoxyl sulfate is a potent protein-bound uremic toxin derived from the microbial metabolism of dietary tryptophan in the gut. It is synthesized in the liver from indole and normally excreted by the kidneys via tubular secretion. In patients with chronic kidney disease (CKD), it accumulates significantly due to impaired renal clearance and poor removal by conventional hemodialysis. Indoxyl sulfate acts as an endogenous agonist for the aryl hydrocarbon receptor (AhR) and promotes oxidative stress, inflammation, and fibrosis in various tissues. Its accumulation is strongly associated with the progression of renal failure, cardiovascular complications, and bone disease, making it a key target for therapeutic interventions aimed at reducing its systemic levels or blocking its downstream signaling.
Gastrointestinal adsorption of indole precursors (AST-120), inhibition of organic anion transporters OAT1 and OAT3 (Probenecid), and antagonism of downstream signaling pathways (Losartan).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Indoxyl sulfate (IS).